Xeris Biopharma Holdings, Inc. (XERS)
Pre-Market:
| Previous Close | 1.7800 |
| Open | 1.8000 |
| Bid | 1.7500 x 800 |
| Ask | 1.7800 x 400 |
| Day's Range | 1.7300 - 1.8000 |
| 52 Week Range | 1.4600 - 3.2600 |
| Volume | |
| Avg. Volume | 1,904,422 |
| Market Cap | 247.197M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings Date | Mar 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 |
ZacksStrength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Simply Wall St.Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions
Key Insights The considerable ownership by retail investors in Xeris Biopharma Holdings indicates that they...
Business WireXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO, April 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris’ Inducement Equity Plan.
